Autoimmune and Metabolic Diseases and the Risk of Early-Onset Colorectal Cancer, a Nationwide Nested Case–Control Study

Author:

Lundqvist Erik12ORCID,Myrberg Ida Hed3ORCID,Boman Sol Erika3,Saraste Deborah45,Weibull Caroline E.3,Landerholm Kalle16,Haapaniemi Staffan12,Martling Anna5,Myrelid Pär17ORCID,Nordenvall Caroline5ORCID

Affiliation:

1. Department of Biomedical and Clinical Sciences, Linköping University, 58183 Linköping, Sweden

2. Department of Surgery, Vrinnevi Hospital, 60379 Norrköping, Sweden

3. Department of Medicine, Division of Clinical Epidemiology, Karolinska University Hospital, Karolinska Institutet, 17177 Stockholm, Sweden

4. Department of Surgery, Södersjukhuset, 11883 Stockholm, Sweden

5. Department of Molecular Medicine and Surgery, Karolinska Institutet, Division of Coloproctology, Center for Digestive Diseases, Karolinska University Hospital, 17177 Stockholm, Sweden

6. Department of Surgery, Ryhov County Hospital, 55305 Jönköping, Sweden

7. Department of Surgery, Linköping University Hospital, 58183 Linköping, Sweden

Abstract

Incidence of early-onset (<50 years) colorectal cancer (EOCRC) is increasing in developed countries. The aim was to investigate autoimmune and metabolic conditions as risk factors for EOCRC. In a nationwide nested case–control study, we included all EOCRC cases in Sweden diagnosed during 2007–2016, together with controls, matched for birth year, sex, and county. Information on exposure of autoimmune or metabolic disease was collected from the National Patient Register and Prescribed Drugs Registry. Hazard ratios (HR) as measures of the association between EOCRC and the exposures were estimated using conditional logistic regression. In total, 2626 EOCRC patients and 15,756 controls were included. A history of metabolic disease nearly doubled the incidence hazard of EOCRC (HR 1.82, 95% CI 1.66–1.99). A sixfold increased incidence hazard of EOCRC (HR 5.98, 95% CI 4.78–7.48) was seen in those with inflammatory bowel disease (IBD), but the risk increment decreased in presence of concomitant metabolic disease (HR 3.65, 95% CI 2.57–5.19). Non-IBD autoimmune disease was not statistically significantly associated with EOCRC. IBD and metabolic disease are risk factors for EOCRC and should be considered in screening guidelines.

Funder

Swedish Research Council

Swedish Cancer Society

Stockholm Cancer Society

Medical Research Council of Southeast Sweden

Region Stockholm

Bengt Ihre Foundation and Mag-Tarmfonden

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference44 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. (2022, October 29). Cancer i Siffror 2018: The National Board of Health and Welfare, The Swedish Cancer Society. Available online: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/statistik/2018-6-10.pdf.

3. Colorectal cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020

4. The increasing incidence of young-onset colorectal cancer: A call to action;Ahnen;Mayo Clin. Proc.,2014

5. Increasing incidence of colorectal cancer among the younger population in Sweden;Petersson;BJS Open,2020

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3